Drug Trial Radar · NCT07090499
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Aug 20, 2025
Primary completion
Jul 8, 2028
Study completion Jul 8, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules. In the second part of the study, groups of people will receive the study drug in dosing regimens deemed to be safe in Part 1. In the third part of the study, people will receive the study drug together with other anti-cancer medicines.
Conditions
- Advanced/Metastatic Solid Tumors
- Bladder Cancer
- Urothelial Carcinoma
- Advanced Non-Small Cell Lung Cancer
- Carcinoma, Non Small Cell Lung
- Carcinoma, Squamous Cell of Head and Neck
- Head and Neck Cancer
- Esophageal Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Esophageal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Cancer
Interventions
PF-08046876Drug
Intravenous administration
PembrolizumabCombination product
Intravenous administration
CisplatinCombination product
Intravenous administration
CarboplatinCombination product
Intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluationTime frame: Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
- Part 1: Number of Participants With Dose-limiting Toxicities (DLTs): MonotherapyTime frame: Baseline to end of DLT evaluation period
- Part 1: Recommended Monotherapy Dose for ExpansionTime frame: Baseline to 30 days post last study drug administration
- Part 2: Recommended Monotherapy Phase 2 DoseTime frame: Baseline to 30 days post last study drug administration
- Part 3: Recommended Combination Phase 2 Dose/ Recommended Combination Dose for ExpansionTime frame: Baseline to 30 days post last study drug administration
Locations
31 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
Administrative Address: UCLA Hematology/Oncology
Los Angeles, California · Recruiting
Ronald Reagan UCLA Medical Center
Los Angeles, California · Recruiting
Santa Monica UCLA Medical Center & Orthopaedic Hospital
Santa Monica, California · Recruiting
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California · Recruiting
Smilow Cancer Hospital - Yale New Haven Health
New Haven, Connecticut · Recruiting
Yale - New Haven Hospital - Yale Cancer Center
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital - Trumbull
Trumbull, Connecticut · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute - Chestnut Hill
Newton, Massachusetts · Recruiting
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center - Conroe
Conroe, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
The University of Texas, MD Anderson Cancer Center - West Houston
Houston, Texas · Recruiting
The University of Texas, MD Anderson Cancer Center - League City
League City, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
The University of Texas, MD Anderson Cancer Center - Sugar Land
Sugar Land, Texas · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Pan American Center for Oncology Trials, LLC
Rio Piedras, Puerto Rico · Recruiting
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Comunidad de, Spain · Recruiting
Barts Cancer Centre at St. Bartholomew's Hospital; Queen Mary University of London
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.